{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:36:01Z","timestamp":1793345761615,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejso.2023.03.226","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T20:42:37Z","timestamp":1680295357000},"page":"1411-1416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery"],"prefix":"10.1016","volume":"49","author":[{"given":"Sohayb","family":"Faleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisheva","family":"Eisenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Francois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tejera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Panet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4104-4021","authenticated-orcid":false,"given":"Najwa","family":"Buhlaiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkis","family":"Meterissian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6850-2192","authenticated-orcid":false,"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2023.03.226_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2022.01.006","article-title":"Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer","author":"Harbeck","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2023.03.226_bib2","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.2217\/fon.15.240","article-title":"The evolving understanding of small HER2-positive breast cancers: matching management to outcomes","volume":"11","author":"Waks","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib4","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib5","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib7","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.19.00066","article-title":"Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer","volume":"37","author":"Tolaney","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib9","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib10","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.21873\/anticanres.12642","article-title":"Factors predictive of sentinel lymph node involvement in primary breast cancer","volume":"38","author":"Malter","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejso.2023.03.226_bib11","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.ejso.2009.06.002","article-title":"Factors predicting the sentinel node metastases in T1 breast cancer tumor: an analysis of 1416 cases","volume":"35","author":"Capdet","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib12","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1918::AID-CNCR12>3.0.CO;2-Y","article-title":"Predictors of axillary lymph node metastases in patients with T1 breast carcinoma","volume":"79","author":"Barth","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2023.03.226_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00000658-199911000-00012","article-title":"Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers","volume":"230","author":"Gajdos","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2023.03.226_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12957-018-1353-2","article-title":"Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients","volume":"16","author":"Majid","year":"2018","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/cncr.20809","article-title":"Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution","volume":"103","author":"Viale","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2023.03.226_bib16","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.breast.2012.09.003","article-title":"Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice","volume":"22","author":"Yoshihara","year":"2013","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2023.03.226_bib17","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1245\/s10434-014-3851-y","article-title":"Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement","volume":"21","author":"Ugras","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4048\/jbc.2021.24.e4","article-title":"Relation between tumor size and lymph node metastasis according to subtypes of breast cancer","volume":"24","author":"Min","year":"2021","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.ejso.2023.03.226_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002213","article-title":"Breast cancer subtype is associated with axillary lymph node metastasis: a retrospective cohort study","volume":"94","author":"He","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejso.2023.03.226_bib20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 Years' follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2023.03.226_bib23","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib25","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS621","article-title":"DECRESCENDO: de-escalation of adjuvant chemotherapy in patients with HER2+\/HR-\/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade","volume":"40","author":"Debien","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2023.03.226_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41523-022-00429-7","article-title":"A prospective trial of treatment de-escalation following neoadjuvant paclitaxel\/trastuzumab\/pertuzumab in HER2-positive breast cancer","volume":"8","author":"Waks","year":"2022","journal-title":"NPJ Breast Cancer"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798323004237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798323004237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:47:12Z","timestamp":1760060832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798323004237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0748798323004237"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2023.03.226","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of nodal metastases in early stage HER2+ breast cancer: Deciding on treatment approach with neoadjuvant chemotherapy vs. upfront surgery","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2023.03.226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}